Back to News
Market Impact: 0.32
AnaptysBio Swings To Profit In Q2 Reflecting $181.5 Mln Tax Benefit
Source: Nasdaq
Healthcare & BiotechCorporate EarningsM&A & RestructuringCompany Fundamentals
AnaptysBio reported a Q2 2026 profit, primarily driven by a significant tax benefit following its separation from First Tracks Biotherapeutics. Collaboration revenue also increased, supported by higher activity, although the available article text does not provide specific financial figures or guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
ANAB0.58
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Paramount will need to release way more movies to make this merger work
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals